Intensity Therapeutics Inc. (INTS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Intensity Therapeutics Inc. (INTS) is down 58.3% since the beginning of the year. At $4 per share, INTS is trading 90.2% below its 52-week high of $44.

Intensity Therapeutics Inc. (INTS) has returned -58.26% so far this year and -66.50% over the past 12 months.

Based on dividend-adjusted daily data since Jun 30, 2023, INTS's average daily return is +0.10%, while the average monthly return is +0.16%. At this rate, an investment would double in approximately 36.1 years.

Historically, 25% of months were positive and 75% were negative. The best month was Dec 2023 with a return of +249.7%, while the worst month was Apr 2025 at -70.2%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.

On a daily basis, INTS closed higher 43% of trading days. The best single day was Oct 30, 2025 with a return of +394.6%, while the worst single day was Jun 12, 2025 at -44.7%.

Intensity Therapeutics Inc. has an annualized alpha of 31.86%, beta of -0.12, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 03, 2023.

• This stock participated in 361.17% of S&P 500 Index downside but only -19.67% of its upside - more exposed to losses than it benefited from rallies.
• Beta of -0.12 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

INTS ranks 42 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Intensity Therapeutics Inc. (INTS) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Intensity Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Intensity Therapeutics Inc. was 98.27%, occurring on Jun 2, 2026. The portfolio has not yet recovered.

The current Intensity Therapeutics Inc. drawdown is 98.27%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Intensity Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Intensity Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.